LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 3, 2022--
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.
The webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the conference webcast will be available on Concert’s website for two weeks following the presentation.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220102005016/en/
Source: Concert Pharmaceuticals, Inc.